Form 4: Coherus BioSciences CFO Reports Stock Transaction Following Vesting of Restricted Stock Units

Coherus BioSciences' Chief Financial Officer, Bryan J. McMichael, had 1,711 shares withheld to cover tax liabilities related to the vesting of restricted stock units.

Summary

• Bryan J. McMichael, the Chief Financial Officer of Coherus BioSciences, Inc., reported a transaction involving the company's common stock.
• On January 20, 2025, 1,711 shares were withheld by the issuer to cover tax obligations associated with the vesting of restricted stock units.
• The price per share for the transaction was $1.39.
• Following this transaction, Mr. McMichael directly owns 22,951 shares of Coherus BioSciences stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to a stock transaction. It does not indicate any positive or negative sentiment.

Industry Context

This is a routine filing related to insider transactions, specifically the vesting of restricted stock units and the subsequent withholding of shares for tax purposes. Such filings are common for publicly traded companies and their executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this transaction is typical for executives receiving stock-based compensation.
• Similar transactions are regularly reported by executives at comparable biotech companies such as Amgen, Gilead, and Biogen, as part of their compensation packages.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects a routine executive compensation event.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Coherus BioSciences, CHRS, Bryan J. McMichael, CFO, stock transaction, restricted stock units, tax withholding, insider trading, Form 4